RESERVE
min $100
If you invest, you're betting Lifescient, Inc. will be worth more than $25M in the future.
Imagine your pet needs long-term pain management—what if there were a way to provide their medication without any ongoing effort from you?
Lifescient's innovative long-acting injectable technology offers medication that lasts from days to months with just one treatment. Our solution enhances pet comfort while freeing pet parents from the burden of managing daily doses.
Placement of the injectable is quick and easily done in a process similar to the placement of a tracking chip. Medication is released according to prescription and after the treatment course is finished, the injectable is safely absorbed.
Prescription compliance guaranteed
Reduced risk of side effects
Elimination of drug diversion and abuse
Improved quality of care
Lifescient was founded by Kamalesh Rao, a pharmaceutical development expert with 25 years of experience. Kamalesh was a key contributor to the team that developed a long-acting injectable for managing opioid withdrawal in humans. After this groundbreaking technology received approval, he envisioned its potential to improve animal care.
We have since created several prototypes of long-acting injectables and successfully demonstrated their technical feasibility. In 2023, the FDA granted a fee waiver to support the development of our first product, an LAI designed to relieve pain in dogs with bone cancer.
Motivated by our mission to enhance animal well-being and elevate care, we have built a team of dedicated professionals to support our work. Lifescient stands as a pioneer in drug delivery advancements, focused on improving the quality of healthcare for pets and the quality of life for those who love and care for them.
Pain stemming from bone cancer in dogs is severe and often inadequately managed. Our first product, LS-001, is an LAI developed to manage the pain associated with this condition.
The FDA has granted us a waiver of sponsor fees to support the development of LS-001 based on the product being intended for a Minor Use in a Major Species (MUMS). This waiver will save the company over $1 million in product development costs. Other benefits include eligibility to seek MUMS grants totaling up to $500,000 and seven years of exclusive marketing rights upon approval of the product by the FDA.
The FDA has also accepted our Investigational New Animal Drug application to develop LS-001. The acceptance by the FDA signifies that Lifescient has provided sufficient preclinical data and safety information to justify testing in clinical trials.
Our strategy leverages our LAI platform to create treatments for chronic conditions in various animal species. We have successfully established and validated the technical feasibility through the development of prototypes for multiple medications.
We are primarily focused on niche areas within the veterinary medicine market, addressing conditions often overlooked by larger pharmaceutical companies. What distinguishes us is our commitment to creating products that meet the needs of both pets and their families, giving us a unique advantage in the industry. To our knowledge, we are the only company developing subdermal long-acting injectable technology specifically designed for veterinary medicine.
The pet pharmaceutical industry has consistently demonstrated resilience during economic downturns and is poised for continued growth as the global pet population expands.
In the U.S. alone, an estimated 65 million dogs and 32 million cats suffer from acute and chronic pain caused by cancer and its treatments each year according to Strategic Market Research. Additionally, 12 million new cancer diagnoses occur in pets annually. Lifescient's long-acting injectable (LAI) treatment for bone cancer in dogs has the potential to alleviate pain for both dogs and cats affected by various cancer-related conditions.
Effective pain management is a critical component of cancer care for animals. This market, valued at $1.8 billion today, is projected to grow to $2.5 billion by 2027, according to Strategic Market Research.
The FDA has granted us a waiver of fees which will save the company more than $1M in development costs.
The FDA has approved our Investigational New Animal Drug application for LS-001, having determined that we have supplied adequate data to establish the safety of our products.
We have established technical feasibility for several medications.
Developed several prototypes of long-acting injectable medications.
Validated market demand via nationwide surveys of veterinarians.
Lifescient's GTM strategy aims to establish the company as a leader in long-acting injectables (LAIs) for pets by leveraging its unique technology, focusing on educating veterinarians and pet owners, and forming strategic partnerships. The goal is to maximize market penetration and create strong, sustainable revenue streams through partnerships, licensing deals, and targeted marketing.
Lifescient is seeking to raise $2 million via this Community Round. The capital we raise from you will be used for the following:
As pets are living longer, age and lifestyle-related diseases are becoming more common. We are well-positioned to capture a significant share of the growing global animal health market. Our products will meet the increasing demand for advanced treatment options, enhancing both the quality of care for pets and the quality of life for their families.
